DISEASE CHARACTERISTICS:

• Diagnosis of any of the following:

  • Epstein-Barr virus (EBV)-positive Hodgkin or non-Hodgkin lymphoma
  • Lymphoepithelioma of any histological subtype
  • EBV (associated)-T/NK-lymphoproliferative disease

  • Severe chronic active EBV infection syndrome (SCAEBV)

    • SCAEBV is defined as a high EBV viral load in plasma or peripheral blood mononuclear cells (PBMC) (> 4,000 genomes/ug PBMC DNA) and/or biopsy tissue positive for EBV

• Meets 1 of the following criteria:

  • In second or subsequent relapse (or in first relapse or has active disease, if immunosuppressive chemotherapy contraindicated, or disease relapsed multiple times and is currently in remission but has a high risk of relapse) OR has primary disease or in first remission, if immunosuppressive chemotherapy is contraindicated, (e.g., developed Hodgkin lymphoma after solid organ transplantation) or if the lymphoma is a second malignancy (e.g., Richter transformation of chronic lymphocytic leukemia)
  • In remission or has minimal residual disease after autologous or syngeneic stem cell transplantation (SCT)
  • In remission or has detectable disease after allogeneic SCT
• At least 50% donor chimerism in either peripheral blood or bone marrow (for patients who have undergone prior allogeneic SCT)

PATIENT CHARACTERISTICS:

• Karnofsky performance status (PS) OR Lansky PS 50-100%
• Life expectancy ≥ 6 weeks
• Hemoglobin > 8.0 g/dL
• Prothrombin time normal
• Bilirubin ≤ 3 times normal
• AST ≤ 5 times normal
• Creatinine ≤ 2 times normal for age
• Not pregnant
• Negative pregnancy test
• Fertile patients must use effective contraception
• HIV negative
• No concurrent severe infection
• No grade III-IV graft-vs-host disease

PRIOR CONCURRENT THERAPY:

• See Disease Characteristics
• More than 1 month since prior investigational therapy